Department of Epidemiology and Prevention, National Institute for Cancer Research, Genova, Italy.
Int J Biol Markers. 2010 Oct-Dec;25(4):200-6.
Prostate cancer is the second most frequent cause of tumor-related deaths in men in Western countries. The selection and evaluation of new markers might help to overcome the limits of the most widely used diagnostic tool, the prostate-specific antigen (PSA) test, often combined with digital rectal examination (DRE). Osteopontin (OPN) is an integrin-binding glycoprotein that has recently been shown to be related to tumor development, progression and metastasis in both experimental and clinical studies. The present study compares plasma OPN levels and tumor presence and grade in a group of PSA/DRE-positive patients referred for diagnostic prostate biopsy.
Plasma OPN levels were measured by enzyme-linked immunosorbent assay in blood samples of 194 PSA/DRE-positive patients referred for diagnostic prostate biopsy. OPN measurements were compared with PSA levels and tumor presence and grade as established by needle biopsy.
Plasma OPN levels were not increased in patients with prostate cancer, and in patients with high-grade prostate cancer the plasma OPN levels were not different from those in patients with low-grade or no prostate cancer.
In PSA/DRE-positive patients referred for diagnostic prostate biopsy, OPN does not appear to be a plasma marker able to detect prostate cancer or high-grade prostate cancer.
在西方国家，前列腺癌是男性肿瘤相关死亡的第二大常见原因。选择和评估新的标志物可能有助于克服最广泛使用的诊断工具——前列腺特异性抗原（PSA）检测的局限性，通常与直肠指检（DRE）联合使用。骨桥蛋白（OPN）是一种整合素结合糖蛋白，最近的研究表明，它与实验和临床研究中的肿瘤发生、发展和转移有关。本研究比较了一组 PSA/DRE 阳性患者的血浆 OPN 水平与肿瘤的存在和分级，这些患者因诊断性前列腺活检而被转介。
通过酶联免疫吸附试验测量了 194 名因诊断性前列腺活检而被转介的 PSA/DRE 阳性患者的血液样本中的血浆 OPN 水平。将 OPN 测量值与通过活检确定的 PSA 水平以及肿瘤的存在和分级进行比较。
患有前列腺癌的患者血浆 OPN 水平没有升高，而患有高级别前列腺癌的患者的血浆 OPN 水平与患有低级别或无前列腺癌的患者没有差异。
在因诊断性前列腺活检而被转介的 PSA/DRE 阳性患者中，OPN 似乎不是一种能够检测前列腺癌或高级别前列腺癌的血浆标志物。
